Dr. Stephen Collins Co-Foundedd and served as Chief Executive Officer & President at Biscayne Neurotherapeutics. He also serves as Chief Executive Officer, Chairman of the Board, Director & President at Insero Health. He served as an Executive Chairman at Xalud Therapeutics. He serves as Board member at Engage Therapeutics. He served as Director at Spinifex Pharmaceuticals. His career has focused on the research and clinical development of therapeutics for CNS disorders. Prior to joining NTP as its CEO, he was Chief Scientific Officer & Vice President of Clinical Affairs of Ovation Pharmaceuticals, a CNS-focused biopharmaceutical company acquired by Lundbeck A/S for $900 million. He joined Ovation in 2003, shortly after its formation and was responsible for establishing the company's R&D group and growing it into a team of over 60 professionals. He was also responsible for establishing the safety and post-marketing research groups as well as all scientific and medical in-licensing activities. His R&D team performed the preclinical and clinical activities for four development programs of Ovation, which resulted in two approved NDAs, two programs in global Phase III, one program in Phase II, multiple INDs, and life-cycle management projects for the firm's marketed assets. Prior to Ovation, he was Global Senior Director of CNS and Pain at Johnson & Johnson, overseeing the early-stage development of neurologic, pain and psychiatric agents. He was also a member of the CNS in-licensing advisory team. Prior to Johnson and Johnson, he worked in Abbott Laboratories' Pharmaceutical and Hospital Products Divisions. While there, he developed drugs for neurologic, psychiatric and pain indications and was responsible for the preclinical and clinical programs that supported the successful filing and approval of multiple NDA and sNDA submissions. Previous to his industry experience, he was in the Departments of Neurology and Neurosciences at Case Western Reserve University, where he founded the Comprehensive Epilepsy Center as well as the Drug Development Center of the Department of Neurology. Prior to that he was on the faculty of the University of California, San Francisco's, Department of Neurology, where he had completed residency and Fellowship training. He earned his MD and PhD at Case Western Reserve University and performed his undergraduate studies in Physics at the University of California, Berkeley.